Silexion reports positive preclinical findings for SIL204 showing lipoprotein-mediated uptake in KRAS-driven cancers

Silexion Therapeutics Corp

SIL204 produced robust, dose-dependent mutant KRAS gene silencing in carrier-free assays; serum lipid depletion significantly reduced knockdown efficiency (P < 0.001).
Exogenous human LDL did not alter silencing potency versus complete serum alone, indicating physiological lipoprotein levels suffice without artificial nanoparticles.
CSDO Mitchell Shirvan cited LDL receptor upregulation in cancer cells; CEO Ilan Hadar highlighted the Phase 2/3 pancreatic program and systemic subcutaneous delivery.
Silexion is advancing SIL204 through Phase 2/3 in locally advanced pancreatic cancer, with site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.